Back to Search
Start Over
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study
- Source :
- JTO Clinical and Research Reports; April 2023, Vol. 4 Issue: 4
- Publication Year :
- 2023
-
Abstract
- In recent years, programmed cell death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy was found to have favorable clinical outcomes in patients with extensive-stage SCLC (ES-SCLC). The usefulness of early tumor shrinkage (ETS) has been reported in various types of cancers. Nevertheless, there have been few reports evaluating ETS in ES-SCLC. Therefore, this study aimed to evaluate the role of ETS in the clinical outcomes of patients with ES-SCLC receiving chemoimmunotherapy.
Details
- Language :
- English
- ISSN :
- 26663643
- Volume :
- 4
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- JTO Clinical and Research Reports
- Publication Type :
- Periodical
- Accession number :
- ejs62440245
- Full Text :
- https://doi.org/10.1016/j.jtocrr.2023.100493